- Trial phase
- Phase 2 (registrational) / Phase 3 recruiting
- Time to market
- If BMS submits a BLA in the coming months, a potential FDA decision could come in late 2027 or early 2028, assuming standard 6-12 month review timelines with RMAT designation benefits.
- Why 4/10
- No hard dated catalyst (PDUFA, pivotal readout, or AdComm) is currently scheduled within the next ~12 months. The registrational Phase 2 QUINTESSENTIAL trial has already read out positive topline results (Sept 8, 2026), but BMS has not yet announced a BLA submission date. The Phase 3 QUINTESSENTIAL-2 trial has an estimated primary completion of December 2027, more than 12 months away. As one pipeline asset within a large diversified pharma, the impact score is moderate.
Watch for BMS to announce a BLA submission for arlo-cel with the FDA, likely in the coming months given the positive registrational Phase 2 results and RMAT designation. A PDUFA date would be the next hard catalyst. Also track the QUINTESSENTIAL-2 Phase 3 trial (primary completion estimated Dec 2027) for potential expansion into earlier-line therapy.
Price Chart
Executive Summary
Arlocabtagene autoleucel (arlo-cel) is Bristol Myers Squibb's investigational GPRC5D-directed CAR-T cell therapy for relapsed/refractory multiple myeloma. On September 8, 2026, BMS announced positive topline results from the registrational Phase 2 QUINTESSENTIAL trial, which met its primary endpoint of overall response rate and all key secondary endpoints in quadruple-class exposed patients. The drug has FDA Regenerative Medicine Advanced Therapy (RMAT) designation. BMS has not yet announced a BLA submission date. A Phase 3 confirmatory trial (QUINTESSENTIAL-2) is recruiting with an estimated primary completion of December 2027. For a large diversified pharma like BMS (market cap ~$120B+), arlo-cel is one of many pipeline assets, and no near-term binary catalyst is currently scheduled.
How It Works
Arlocabtagene autoleucel is a personalized cell therapy (CAR-T) for multiple myeloma, a blood cancer. A patient's own immune cells (T cells) are collected, genetically engineered in a lab to recognize and attack a protein called GPRC5D found on myeloma cells, then infused back into the patient as a one-time treatment. The engineered cells multiply inside the body and seek out and destroy cancer cells carrying the GPRC5D target.
Trial Status
The registrational Phase 2 QUINTESSENTIAL trial (NCT06297226) met its primary and key secondary endpoints in September 2026. The Phase 3 QUINTESSENTIAL-2 trial (NCT06615479) is actively recruiting approximately 440 patients, comparing arlo-cel against standard of care in lenalidomide-refractory RRMM, with estimated primary completion in December 2027.
The Two-Sided Case
Upcoming Catalysts
- BLA submission announcement (timing unconfirmed)
- Full data presentation at a medical meeting (likely ASH or EHA)
- QUINTESSENTIAL-2 Phase 3 interim or final analysis (estimated primary completion Dec 2027)
Source Filing
The SecBot filing or press-release report that triggered this drug report:
BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report